Jazz Pharmaceuticals PLC (JAZZ) Expected to Post Quarterly Sales of $461.36 Million

Equities analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report sales of $461.36 million for the current quarter, according to Zacks. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $490.40 million and the lowest estimate coming in at $449.47 million. Jazz Pharmaceuticals posted sales of $436.40 million in the same quarter last year, which suggests a positive year over year growth rate of 5.7%. The company is scheduled to report its next earnings results on Tuesday, February 26th.

On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.88 billion for the current financial year, with estimates ranging from $1.86 billion to $1.92 billion. For the next year, analysts anticipate that the firm will report sales of $2.07 billion, with estimates ranging from $1.99 billion to $2.19 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. The company had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. During the same quarter in the previous year, the firm posted $3.22 EPS. The firm’s quarterly revenue was up 14.0% on a year-over-year basis.

A number of research analysts have issued reports on the company. Leerink Swann boosted their price target on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, August 17th. BidaskClub upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 28th. Morgan Stanley set a $168.00 price target on Jazz Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 28th. Zacks Investment Research reiterated a “hold” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, November 13th. Finally, Mizuho reiterated a “neutral” rating and set a $173.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, October 15th. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $189.76.

In other news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction on Friday, September 14th. The stock was sold at an average price of $165.20, for a total value of $33,040.00. Following the completion of the sale, the executive vice president now owns 25,372 shares in the company, valued at $4,191,454.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Matthew P. Young sold 700 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $162.70, for a total value of $113,890.00. Following the completion of the sale, the chief financial officer now owns 33,468 shares of the company’s stock, valued at approximately $5,445,243.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,600 shares of company stock valued at $1,063,472. Insiders own 3.90% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 64.0% during the second quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock valued at $753,311,000 after purchasing an additional 1,706,417 shares during the last quarter. FMR LLC lifted its holdings in shares of Jazz Pharmaceuticals by 12.1% during the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock valued at $1,143,203,000 after purchasing an additional 715,595 shares during the last quarter. AGF Investments Inc. purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $78,345,000. Voya Investment Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $70,215,000. Finally, Fiera Capital Corp purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $54,662,000. Institutional investors and hedge funds own 91.53% of the company’s stock.

JAZZ stock traded down $2.33 during trading on Monday, reaching $141.17. 975,543 shares of the company’s stock were exchanged, compared to its average volume of 729,139. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.16 and a current ratio of 4.29. Jazz Pharmaceuticals has a 1-year low of $130.15 and a 1-year high of $184.00. The firm has a market capitalization of $8.66 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.94.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Return on Investment (ROI) Defined, Explained

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply